Testing a new antifungal for mold infections in immunocompromised people
Part of Infections clinical trials.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a weakened immune system (due to a stem cell or bone marrow transplant, blood cancer, recent low white blood cell count for more than 10 days, long-term steroid use, or an inherited immune disorder).
- You have a suspected or proven mold infection, based on a lab test or a chest CT scan.
- You have not received more than 4 days of antifungal treatment for this infection before the study starts.
- You do not have severe liver, kidney, heart, or lung problems, and you are not on dialysis.
- If you are a woman who can become pregnant, you must use highly effective birth control and have negative pregnancy tests; men must use a condom or be vasectomized.
- You are willing to come for study visits and follow all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
This study tracks how your immune system responds to serious mold infections, like aspergillosis or mucormycosis. It may help doctors understand why some infections are hard to treat and could lead to better care.
This study looks at how safe and effective a medicine called liposomal amphotericin B is for treating mold infections in people who have had a liver transplant. It may help doctors understand better ways to fight these serious infections.
This trial tests a new treatment using a patient's own immune cells, called NK cells, that are modified to better fight severe fungal infections that are not responding to standard antifungal medicines. The aim is to see if this approach can help control or clear the infection.
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
This study tests a new imaging agent that may help doctors see mold infections in the body. It involves healthy volunteers and people with mold infections, and aims to improve how these infections are detected and monitored.
Hear when a new Invasive Mould Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.